ClinicalTrials.gg
CompletedNCT02056847SIPHONUpdated Mar 8, 2018

to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia

A Phase 4 interventional study of Pitavastatin calcium 4mg and Pitavastatin calcium 2mg in HbA1c Level Associated With Lipid Compositions, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2013, registered Feb 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Hyperlipidemias with a site in Korea, Republic of — 3 open to participants now, 5 under way, 2 of them phase 3. Hyperlipidemias · Korea, Republic of.

Enrollment
16th of 85
313 · median 80
Started
2013
with 12 others
Phase 4
8 of 89
none open now
Registered
32nd of 89
by date

Among the 89 studies in Hyperlipidemias with a site in Korea, Republic of, this one is the 16th largest by enrollment of the 85 interventional ones that give a count, is one of 13 that started in 2013, is one of 8 in phase 4, and was the 32nd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 89 studies in Hyperlipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Hyperlipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Primary Objective

: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG).

H0: µT-µC ≥ 0.4 vs H1: µT-µC \< 0.4

µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)

Read the detailed description

Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group: Pitavastatin calcium (LIVALO) 2mg tab

Study Site: Multi-centers in Korea

Period: For 24months after IRB approval at each site (Including 12months of subject enrollment period)

Efficacy End points

A. Primary end point The change of HbA1c before and after taking LIVALO

B. Secondary end point

  1. Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need taking diabetes medication)
  2. Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration
  3. Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration
  4. The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)
  5. The changes of hs-CRP
  6. The changes of Adiponectin
  7. The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]

Statistical Methods

  1. Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the HbA1c variation before and after taking LIVALO by groups. In order to verify noninferiority of test drug, check that upper limit of confidence interval of the one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the control group and the test group, before and after taking LIVALO.

    B. Secondary efficacy endpoint analysis Continuous variables

    :Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C, HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each visit and in each group. In comparison with intergroup, using two-sample t-test for normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also In comparison with the same group, using paired t-test for normal distribution and using Wilcoxon signed rank test for non-normal distribution.

    Discrete variables

    : The number and percentage of the subjects for incidence of DM and cardiovascular event are described of each group and the ratio of the intergroup comparison use χ2-test or Fisher's exact test.

  2. Safety All the AEs and the ADRs which manifested more than once are described by the frequency and percentage of each group and use χ2-test or Fisher's exact test for intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs are analyzed descriptive statistics quantity of each group, and in comparison with intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum test for non-normal distribution. Also, In comparison with the same group, use paired t-test for normal distribution and use Wilcoxon signed rank test for non-normal distribution.

Clinical laboratory test is analyzed the frequency and percentage of the outside normal range of subjects, and using χ2-test or Fisher's exact test with intergroup.

03

Conditions studied

  • HbA1c Level Associated With Lipid Compositions

Browse trials for

Keywords

  • Livalo, pitavastatin, hyperlipidemia, IFG
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and Female patients who are more than 20 years old or 70 years old or less.
  2. Patient who voluntarily sign on written form
  3. Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia
  4. Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥ 100mg/dL and \< 126mg/dL when FPG measured twice.

Exclusion criteria

Exclusion Criteria:

  1. Patient who has familial hypercholesterolemia
  2. Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes mellitus) at the screening visit (Diagnostic criteria of DM: ≥ 6.5%)
  3. Patient who has received antidiabetic within 6weeks to the screening visit
  4. Patient who has been taking insulin continuously or to be needed in the future
  5. Patient who has a history of gastrectomy
  6. Patient who is suspected or diagnosed with malignant tumor within last 10 years
  7. Patient who has serious pancreatic disease or endocrine disorders
  8. Patient who currently takes Cyclosporine
  9. Patient who has a medical history of to Pitavastatin calcium
  10. Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)
  11. Patient who has suspected liver dysfunction (more than 2.5 times the or ALT)
  12. Patient who has more than 3 times the upper limit of normal CPK
  13. Patient who is breastfeeding, pregnant or planning pregnancy
  14. Patient who deemed inappropriate as subject in the opinion of the Principal Investigator or Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
313 participants (actual)

Study arms

  • Active comparator
    Pitavastatin calcium 4mg

    Pitavastatin calcium (LIVALO®) 4mg, once a day

    Drug: Pitavastatin calcium 4mg

  • Active comparator
    Pitavastatin calcium 2mg

    Pitavastatin calcium (LIVALO®) 2mg, once a day

    Drug: Pitavastatin calcium 2mg

Interventions

06

What researchers measure

Primary outcomes

  1. The change of HbA1c before and after taking LIVALO®

    Time frame: 24 weeks after taking IP

Secondary outcomes

  1. Incidence of diabetes

    based; FPG ≥126mg/dL or to need taking diabetes medication

    Time frame: within 1year after registration

  2. Incidence of total cardiovascular (TVR-MACE) events

    Time frame: within 1 year after registration

  3. The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)

    Time frame: 24weeks and 1 year after registration

  4. The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels

    The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR \[fasting insulin(µIU/mL) X fasting glucose(mg/dL)\]/405 HOMA β \[360 X fasting insulin(µIU/mL)\]/\[fasting glucose(mg/dL)-63\]

    Time frame: 24weeks and 1 year after registration

07

Study locations

1 site
  • JW pharmaceutical
    Seoul, 137-864, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in May 2017, 44 months.

Of 18 phase 4 interventional studies under Hyperlipidemias, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2014
First posted
Feb 6, 2014
StartActual
Sep 2013
Primary completionActual
May 2017
CompletionActual
May 2017
Last update
Mar 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02056847
Lead sponsor
JW Pharmaceutical
Collaborators
The Catholic University of Korea, Kyunghee University Medical Center, Korea University Guro Hospital, Dong-A University Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Seoul National University Hospital, Ajou University School of Medicine, Gangnam Severance Hospital, Severance Hospital, Yeungnam University Hospital, Ulsan University Hospital, Eulji University Hospital, Asan Medical Center, Chonnam National University Hospital, Chonbuk National University Hospital, Chungnam National University Hospital, Hallym University Medical Center
Responsible party
Sponsor
First posted
Feb 6, 2014
Start date
Sep 2013
Primary completion
May 2017
Completion
May 2017
Last update
Mar 8, 2018

Study contacts

NamSik Chung, M.D., Ph D.
principal investigator · Severance Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion